ArticleBioMedicine2026
Adjunctive hyperbaric oxygen therapy for chronic diabetic foot ulcer unresponsive to standard care: A case report.
Article in BioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus and are often challenging to treat, particularly in patients who fail to respond to standard wound care. Adjunctive therapies such as hyperbaric oxygen therapy (HBOT) have shown potential in promoting wound healing in chronic cases. Case presentation: A 66-year-old male with a 10-year history of type 2 diabetes mellitus presented with a chronic, non-healing DFU on the right foot. Despite oral antibiotic therapy and conventional wound management, the ulcer demonstrated progressive necrosis, persistent infection, and tissue exposure. Wound culture identified Klebsiella oxytoca. After targeted antibiotic treatment, the patient underwent 35 sessions of HBOT at 2.4 ATA for 90 min per session, five days per week, in conjunction with hydrogel dressings and structured wound care strategies. Results: Over the treatment course, the wound exhibited substantial clinical improvement, including reduced edema, infection control, emergence of granulation tissue, and near-complete epithelialization. No complications occurred during HBOT, and the patient tolerated the therapy well. Conclusion: This case demonstrates the potential benefits of HBOT as an adjunctive therapy in chronic DFUs unresponsive to standard care. HBOT, when combined with modern wound care strategies, may accelerate healing and reduce the risk of amputation in select patient populations. Further research is warranted to refine treatment protocols and establish evidence-based criteria for patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.